WO2004089343A1 - Comprimes hydrosolubles - Google Patents

Comprimes hydrosolubles Download PDF

Info

Publication number
WO2004089343A1
WO2004089343A1 PCT/IB2004/001104 IB2004001104W WO2004089343A1 WO 2004089343 A1 WO2004089343 A1 WO 2004089343A1 IB 2004001104 W IB2004001104 W IB 2004001104W WO 2004089343 A1 WO2004089343 A1 WO 2004089343A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
hydrochloride
tablet
soluble
tablet according
Prior art date
Application number
PCT/IB2004/001104
Other languages
English (en)
Inventor
Deepak Murpani
Ashish Madan
Sanjeev Sethi
Rajiv Malik
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2004089343A1 publication Critical patent/WO2004089343A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to water-soluble tablets that dissolve to form clear aqueous solutions, and processes for their preparation.
  • Dispersible tablets are dispersed in water prior to dosing and the suspension formed then is consumed by the patient. Although convenient, the suspension gives the feeling of grittiness in the mouth due to the presence of water insoluble excipients, such as dismtegrants. Moreover, there is the possibility of dose loss because the active ingredient may get trapped in these insoluble excipients.
  • effervescent tablet in addition to the problems associated with dispersible tablets, has the problem of stability.
  • These dosage forms contain an acid/base couple to produce effervescence. In the presence of water, these ingredients react to produce carbon dioxide and effervescence. During the process of manufacture, care must be taken to avoid contact with moisture.
  • This dosage form requires special manufacturing facilities in order to maintain conditions of low relative humidity and low temperatures, which subsequently increases costs and overhead. Additionally, effervescent tablets require special packaging to avoid any moisture absorption during storage. These requirements make the manufacturing of effervescent dosage forms complicated and undesirable.
  • U.S. Patent No. 3,692,896 discloses the preparation of a water-soluble tablet by direct compression.
  • the tablet includes a water-soluble active ingredient, lactose, and micronized polyethylene glycol as a lubricant. Lactose undergoes a Malliard reaction in the presence of free amines and as a result slows the disintegration of the tablet. Most active ingredients tend to have an unacceptable taste that becomes more prominent when administered in solution form. Therefore, there is an unmet need for a dosage form that effectively taste masks the active ingredient without decreasing patient compliance. Summary of the Invention
  • a water-soluble tablet in one general aspect there is provided a water-soluble tablet.
  • the tablet includes (a) at least one water-soluble active ingredient; (b) one or more water soluble sugar alcohols; (c) one or more water-soluble lubricants; and (d) one or more pH modifiers.
  • the tablet dissolves in less than about three minutes in less than about 30 ml of water to give a clear solution.
  • Embodiments of the tablet may include one or more of the following features.
  • the tablet may dissolve in water within two minutes or one minute to give a clear solution.
  • the tablet may be dissolved in less than about 20 ml or 15 ml of water.
  • the water-soluble active ingredient may have a solubility of at least 1 part in 30 parts of water at a neutral, acidic or alkaline pH.
  • the therapeutic unit dose of the active ingredient may be soluble in about 30 ml of water in an acidic, alkaline or neutral pH.
  • the water-soluble active ingredient may make up not more than 95% weight by weight of the tablet.
  • the water-soluble active ingredient may be one or more of metformin hydrochloride, gabapentin, glibenclamide, glipizide, diltiazem hydrochloride, verapamil hydrochloride, bupropion hydrochloride, propranolol hydrochloride, dextromethorphan hydrobromide, diphenhydramine hydrochloride, disopyramide hydrochloride, tramadol, fluoxetine hydrochloride, paroxetine hydrochloride, pentoxifylline hydrochloride, and diclofenac sodium.
  • the water-soluble active ingredient may be metformin hydrochloride, a combination of metformin hydrochloride and glibenclamide, a combination of metformin hydrochloride and glipizide, or gabapentin.
  • the one or more sugar alcohols may be one or more of sorbitol, mannitol, spray dried mannitol, xylitol, erythritol isomalt, hydrogenated starch hydrolysates and combinations thereof.
  • the sugar alcohol may be xylitol, mannitol, or a mixture of xylitol and mannitol.
  • the one or more water-soluble lubricants may be one or more of DL-leucine, sodium lauryl sulphate, magnesium lauryl sulphate and polyethylene glycol.
  • the lubricant may be pulverized micronised polyethylene glycol.
  • the polyethylene glycol may have a particle size with 90% of the particles having a size less than 250 ⁇ m, a molecular weight of from about 3,500 to about 20,000, or a molecular weight of from about 3,500 to about 8,000.
  • the pH modifier may be one or more of potassium hydroxide, sodium hydroxide, monosodium citrate, citric acid and the like.
  • the tablet may further include one or more additional pharmaceutical excipients.
  • the one or more additional pharmaceutical excipients may be one or more of binders, sweeteners, and flavouring agents.
  • the binder may be one or more of soluble starch, polyvinylpyrrolidone, cellulose ethers, gums and carboxyvinyl polymer(s).
  • the sweetener may be one or more of aspartame, saccharine sodium, glycine, lactose, dextrose, fructose, maltose, sorbitol and sucrose.
  • the tablet may include one or more water-soluble active ingredients, xylitol, spray-dried mannitol and micronized polyethylene glycol and the tablet dissolves in about 30 ml of water within three minutes to give a clear solution.
  • a process for the preparation of a water- soluble tablet includes compressing a mixture of (a) at least one water- soluble active ingredient; (b) one or more water soluble sugar alcohols; (c) one or more water-soluble lubricants; and (d) one or more pH modifiers.
  • the tablet dissolves in about 3 minutes in about 30 ml of water to give a clear solution.
  • Embodiments of the process may include one or more of the following features or those described above.
  • the mixture may be formulated into a tablet by direct compression.
  • the process may further include granulating the mixture prior to compression.
  • the granulating may be wet granulation or dry granulation.
  • the one or more water-soluble active ingredients may be metfo ⁇ nin hydrochloride, gabapentin, glibenclamide, glipizide, diltiazem hydrochloride, verapamil hydrochloride, bupropion hydrochloride, propranolol hydrochloride, dextromethorphan hydrobromide, diphenhydramine hydrochloride, disopyramide hydrochloride, tramadol, fluoxetine hydrochloride, paroxetine hydrochloride, pentoxifylline hydrochloride, and diclofenac sodium.
  • the one or more water soluble sugar alcohols may be one or more of sorbitol, mannitol, spray dried mannitol, xylitol, erythritol isomalt and hydrogenated starch hydrolysates and combinations thereof.
  • the one or more water-soluble lubricants may be one or more of DL-leucine, sodium lauryl sulphate, magnesium lauryl sulphate and polyethylene glycol.
  • the one or more pH modifiers may be one or more of potassium hydroxide, sodium hydroxide, monosodium citrate, citric acid and the like.
  • the mixture may include additional pharmaceutical excipients.
  • the additional pharmaceutical excipients may be one or more of binders, sweeteners, and flavouring agents.
  • the binder may be one or more of soluble starch, polyvinylpyrrolidone, cellulose ethers, gums and carboxyvinyl polymer(s).
  • the sweetener may be one or more of aspartame, saccharine sodium, glycine, lactose, dextrose, fructose, maltose, sorbitol and sucrose.
  • a method of treating a condition includes administering a water-soluble tablet that includes (a) at least one water- soluble active ingredient; (b) one or more water soluble sugar alcohols; (c) one or more water-soluble lubricants; and (d) one or more pH modifiers.
  • the tablet dissolves in less than about three minutes in less than about 30 ml of water to give a clear solution.
  • Embodiments of the method may include one or more of the following features or those described above.
  • the one or more water-soluble active ingredients may be metformin hydrochloride, gabapentin, glibenclamide, glipizide, diltiazem hydrochloride, verapamil hydrochloride, bupropion hydrochloride, propranolol hydrochloride, dextromethorphan hydrobromide, diphenhydramine hydrochloride, disopyramide hydrochloride, tramadol, fluoxetine hydrochloride, paroxetine hydrochloride, pentoxifylline hydrochloride, and diclofenac sodium.
  • the one or more water soluble sugar alcohols may be one or more of sorbitol, mannitol, spray dried mannitol, xylitol, erythritol isomalt and hydrogenated starch hydrolysates and combinations thereof.
  • the one or more water-soluble lubricants may be one or more of DL-leucine, sodium lauryl sulphate, magnesium lauryl sulphate and polyethylene glycol.
  • the one or more pH modifiers comprises one or more of potassium hydroxide, sodium hydroxide, monosodium citrate, citric acid and the like.
  • a tablet having a pleasant taste and that is capable of dissolving within three minutes in water without residual particulate matter, can be easily prepared through the use of water soluble sugar alcohols in the place of commonly used saccharides.
  • the water-soluble sugar alcohols not only aid in the quick disintegration of the tablet but also provide compressible properties to the bulk.
  • Sugar alcohols do not add moisture or contribute to moisture pickup and are chemically inert. These properties make sugar alcohols useful excipients for tablets because they protect water-sensitive active ingredients from degradation and do not react with the active ingredient.
  • pH modifiers optionally may be added to fo ⁇ nulations containing active ingredients that have poor solubility in neutral and acidic environments.
  • the inventors also have developed a process for preparing water-soluble tablets by direct compression of the one or more water-soluble active ingredients, one or more water- soluble sugar alcohols, one or more water-soluble lubricant, and, optionally, one or more pH modifiers.
  • the process provides tablets that are rapidly soluble in aqueous media and provide an easy mode of administration. These tablets can also be swallowed like other conventional tablets.
  • water-soluble tablet as used herein means an uncoated tablet that dissolves in water, as described in the British Pharmacopoeia 1988, Vol. II.
  • the solution produced may be slightly opalescent due to added substances used in the manufacture of the tablets.
  • water-soluble active ingredient herein means an active ingredient having solubility of at least about 1 part in 30 parts of water. This term also includes those active ingredients in which 1 part of an active ingredient dissolves in more than 30 parts of water, but under acidic or alkaline conditions, the solubility is increased up to 1 part in 30 parts of water.
  • water-soluble active ingredient also includes those active ingredients having a therapeutic unit dose in an amount that dissolves in about 30ml, in particular in about 20ml and more particularly in about 15 ml water in acidic, alkaline or neutral pH to give clear solution.
  • the pH adjustment can be accomplished using acidic or basic pharmaceutical excipients.
  • Suitable water-soluble active ingredients include one or more of metformin hydrochloride, gabapentin, glipizide, glibenclamide, diltiazem hydrochloride, verapamil hydrochloride, bupropion hydrochloride, propranolol hydrochloride, dextromethorphan hydrobromide, diphenhydramine hydrochloride, disopyramide hydrochloride, tramadol, fluoxetine hydrochloride, paroxetine hydrochloride, pentoxifylline hydrochloride, diclofenac sodium and the like.
  • the water-soluble active ingredient may be present in an amount of up to about 95% weight by weight of the tablet.
  • Suitable water-soluble sugar alcohols include one or more of sorbitol, mannitol, spray-dried mannitol, xylitol, erythritol, isomalt and hydrogenated starch hydrolysates and combinations thereof.
  • xylitol and spray dried mannitol may be used.
  • Suitable mannitol may be spray-dried mannitol, which is available under the trade name Pearlitol.
  • Mannitol is a free flowing, directly compressible sugar alcohol that has a cooling taste due to a negative heat of solution. Mannitol also gives tablets good hardness and facilitates a quick dissolution.
  • Spray dried mannitol has a particle shape that allows it to be free-flowing and easily mixed with other ingredients. These properties allow it to be used with high dose active ingredients that may exhibit flow problems. Mixing these typically difficult-to-compress active ingredients with spray-dried mannitol makes it possible to formulate a suitable tablet.
  • the water-soluble sugar alcohol may be present in an amount of from about 10% to about 95% weight by weight of the tablet. For example, the water-soluble sugar alcohol may be present in amount of from about 30% to about 70% weight by weight of the tablet.
  • Suitable water-soluble lubricants include one or more of DL-leucine, sodium lauryl sulphate, magnesium lauryl sulphate and polyethylene glycol.
  • polyethylene glycol For example, pulverized or micronised polyethylene glycol, with 90% of the particles having a size that is less than 250 ⁇ m and a molecular weight that is from about 1500 to about 20,000 may be used.
  • Polyethylene gfycols having molecular weights of from about 3500 to about 8000 may also be used.
  • the water-soluble lubricant may be present in an amount of from about 0.1 % to about 10% weight by weight, and in particular, in an amount of from about 2% to about 10% weight by weight of the tablet.
  • Suitable pH modifiers include one or more of potassium hydroxide, sodium hydroxide, monosodium citrate, citric acid and the like.
  • the tablet may include one or more of binders, sweeteners and flavouring agents.
  • Suitable binders include one or more of soluble starch, polyvinylpyrrolidone, cellulose ethers, gums, carboxyvinyl polymer(s) and combinations thereof.
  • Suitable sweeteners include one or more of aspartame, saccharine sodium, glycine, lactose, dextrose, fructose, maltose, sorbitol and sucrose.
  • Suitable flavouring agents include one or more of strawberry aroma, raspberry aroma, cherry flavour, lime flavour, fruit extracts, citrates and tartarates.
  • the tablet can be prepared by any conventional tableting method.
  • the water-soluble active ingredient, one or more sugar alcohols, water-soluble lubricant, pH modifiers and other optional water-soluble excipients may be sifted through a mesh of suitable size.
  • the sifted blend may be mixed with a water-soluble lubricant and compressed using suitable tooling.
  • the active ingredient may be mixed with a binder and granulated with purified water.
  • the water-soluble active ingredient may be mixed with one or more sugar alcohols, and optionally water-soluble lubricants, and granulated with a binder solution.
  • the granules can be dried and mixed with other excipient(s) and water-soluble lubricants, and compressed using suitable tooling.
  • the blend of all the ingredients can be compacted to make granules of suitable size, the resulting granules mixed with a water-soluble lubricant, and compressed.
  • Tablets are a preferred final dosage form, however, granules that include the water- soluble active ingredient and one or more water-soluble sugar alcohols, water-soluble lubricant, pH modifiers and other optional excipients can also be prepared and packed into sachets, bottles or other suitable packaging devices meant for unit/multiple dosage. These granules can be dissolved in water to give a clear solution and consumed.
  • Tablets were formulated with the following ingredients:
  • Metformin hydrochloride and polyvinyl pyrrolidone were mixed in a blender and granulated with purified water. The granules were dried and mixed with spray-dried mannitol, xylitol, aspartame and monosodium citrate. The above blend was then mixed with the micronized polyethylene glycol and compressed using the appropriate tooling. The tablets obtained, when dropped in 30 ml of water, dissolved quickly to give a clear solution.
  • the compositions of Examples 1 and 2, prepared using metformin hydrochloride as the water-soluble active ingredient are listed in Table 1.
  • Water-soluble tablets of gabapentin and metformin hydrochloride with glibenclamide can be prepared as disclosed in Tables 2 and 3, which correspond to Examples 3-5.
  • Glibenclamide has a poor solubility in neutral or acidic pH environments. In a basic environment, however, glibenclamide is more soluble.
  • a pH modifier can be used to provide, for example, a more basic environment. Water-soluble tablets of metformin hydrochloride- and glibenclamide including a pH modifier, namely, sodium hydroxide, were prepared. When the tablet was dropped in 30 ml of water, it dissolved quickly to give a clear solution.
  • sodium hydroxide is exemplified here, other basic pH modifiers can be used instead and the use of sodium hydroxide merely exemplifies the concept.
  • suitable pH modifiers include potassium hydroxide, monosodium citrate, citric acid and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention se rapporte à des comprimés hydrosolubles qui se dissolvent pour former des solutions aqueuses transparentes, ainsi qu'à leurs procédés de préparation. Le comprimé comprend (a) au moins un principe actif hydrosoluble; (b) au moins un alcool glucidique hydrosoluble; (c) au moins un lubrifiant hydrosoluble; et (d) au moins un agent modifiant le pH. Ce comprimé se dissout en moins de trois minutes approximativement dans moins de 30 ml d'eau environ, pour donner une solution transparente.
PCT/IB2004/001104 2003-04-09 2004-04-08 Comprimes hydrosolubles WO2004089343A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN591DE2003 2003-04-09
IN591/DEL/2003 2003-04-09

Publications (1)

Publication Number Publication Date
WO2004089343A1 true WO2004089343A1 (fr) 2004-10-21

Family

ID=33156199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001104 WO2004089343A1 (fr) 2003-04-09 2004-04-08 Comprimes hydrosolubles

Country Status (1)

Country Link
WO (1) WO2004089343A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057968A2 (fr) * 2006-11-02 2008-05-15 The Coca-Cola Company Composition antidiabétique renfermant un édulcorant très puissant
WO2009050490A1 (fr) * 2007-10-19 2009-04-23 Reckitt Benckiser Healthcare (Uk) Limited Composition orale comprenant un agent rafraîchissant
DE102007052870A1 (de) * 2007-11-02 2009-05-07 Sasol Germany Gmbh Verwendung von Polyethylenglykol-Pulvern und Zusammensetzungen enthaltend diese
CN102266351A (zh) * 2011-07-28 2011-12-07 白求恩医科大学制药厂 一种肌氨肽苷注射液药物组合物及其制备方法
US8663684B2 (en) 2008-09-19 2014-03-04 Molkerei Meggle Wasserburg Gmbh & Co. Kg Lactose and cellulose-based tableting aid
US10463620B2 (en) 2014-10-16 2019-11-05 Cargill, Incorporated Process for preparing a directly compressible erythritol and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1248190A (en) * 1968-09-12 1971-09-29 Bristol Myers Co Chewable tablets comprising a form of tetracycline
DE3909520A1 (de) * 1988-03-25 1989-10-05 Ciba Geigy Ag Feste, schnell zerfallende darreichungsformen
US6284275B1 (en) * 1998-08-31 2001-09-04 Andrx Pharmaceuticals, Inc. Controlled release tablet having a unitary core

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1248190A (en) * 1968-09-12 1971-09-29 Bristol Myers Co Chewable tablets comprising a form of tetracycline
DE3909520A1 (de) * 1988-03-25 1989-10-05 Ciba Geigy Ag Feste, schnell zerfallende darreichungsformen
US6284275B1 (en) * 1998-08-31 2001-09-04 Andrx Pharmaceuticals, Inc. Controlled release tablet having a unitary core

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057968A2 (fr) * 2006-11-02 2008-05-15 The Coca-Cola Company Composition antidiabétique renfermant un édulcorant très puissant
WO2008057968A3 (fr) * 2006-11-02 2008-09-12 Coca Cola Co Composition antidiabétique renfermant un édulcorant très puissant
JP2010509232A (ja) * 2006-11-02 2010-03-25 ザ・コカ−コーラ・カンパニー 高甘味度甘味料を含む抗糖尿病組成物
JP2014139224A (ja) * 2006-11-02 2014-07-31 The Coca-Cola Company 高甘味度甘味料を含む抗糖尿病組成物
WO2009050490A1 (fr) * 2007-10-19 2009-04-23 Reckitt Benckiser Healthcare (Uk) Limited Composition orale comprenant un agent rafraîchissant
EP3093010A1 (fr) * 2007-10-19 2016-11-16 Reckitt Benckiser Healthcare (UK) Limited Composition orale comprenant un agent rafraîchissant
US9764034B2 (en) 2007-10-19 2017-09-19 Reckitt Benckiser Healthcare (Uk) Limited Oral composition comprising a cooling agent
DE102007052870A1 (de) * 2007-11-02 2009-05-07 Sasol Germany Gmbh Verwendung von Polyethylenglykol-Pulvern und Zusammensetzungen enthaltend diese
US8663684B2 (en) 2008-09-19 2014-03-04 Molkerei Meggle Wasserburg Gmbh & Co. Kg Lactose and cellulose-based tableting aid
CN102266351A (zh) * 2011-07-28 2011-12-07 白求恩医科大学制药厂 一种肌氨肽苷注射液药物组合物及其制备方法
US10463620B2 (en) 2014-10-16 2019-11-05 Cargill, Incorporated Process for preparing a directly compressible erythritol and uses thereof

Similar Documents

Publication Publication Date Title
US11013762B1 (en) Pharmaceutical compositions
US8425935B2 (en) Pharmaceutical formulation for producing rapidly disintegrating tablets
US8685457B2 (en) Pharmaceutical formulation for the production of rapidly disintegrating tablets
JP2006501234A (ja) 錠剤製造における、クエン酸およびラクチトール等の水溶性糖水溶液の、造粒液としての使用
ZA200501419B (en) Fast dissolving and taste masked oral dosage form comprising sildenafil
JPH01313420A (ja) 医薬咀しゃく錠組成物
WO2004089343A1 (fr) Comprimes hydrosolubles
EP2046337A2 (fr) Formes solides contenant du méloxicam ayant un gout buccal amélioré et procédé pour leur préparation
WO2004082664A1 (fr) Comprimes de metformine solubles dans l'eau
EP2609911A1 (fr) Nouveau procédé de préparation de formulations de flurbiprofène se désintégrant oralement
WO2019043427A1 (fr) Formes posologiques à auto-dispersion rapide de déférasirox
WO2013098399A1 (fr) Formulation de mozavaptan
JP2014507454A (ja) 速崩錠を製造するための医薬製剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 5104/DELNP/2005

Country of ref document: IN

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase